重新审视 5α-还原酶抑制剂与前列腺癌风险。
Revisiting 5α-reductase inhibitors and the risk of prostate cancer.
机构信息
Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
出版信息
Nat Rev Urol. 2018 Jul;15(7):400-401. doi: 10.1038/s41585-018-0018-9.
Abstract
The role of 5α-reductase inhibitors (5-ARI) in prostate cancer chemoprevention remains a controversy, as cancer prevention trials with 5-ARIs have shown a decreased incidence of low-grade prostate cancer but a potential increased risk in high-grade disease. Recent studies have shed light on the long-term safety of 5-ARIs in terms of influencing prostate cancer risk.
摘要
5α-还原酶抑制剂（5-ARI）在前列腺癌化学预防中的作用仍然存在争议，因为使用 5-ARI 的癌症预防试验显示低级别前列腺癌的发病率降低，但高级别疾病的潜在风险增加。最近的研究揭示了 5-ARI 对前列腺癌风险影响的长期安全性。
相似文献
1
Revisiting 5α-reductase inhibitors and the risk of prostate cancer.重新审视 5α-还原酶抑制剂与前列腺癌风险。
Nat Rev Urol. 2018 Jul;15(7):400-401. doi: 10.1038/s41585-018-0018-9.
2
Prostate cancer chemoprevention with 5α-reductase inhibitors.5α-还原酶抑制剂用于前列腺癌化学预防
Urol Oncol. 2012 Sep;30(5):553-4. doi: 10.1016/j.urolonc.2011.02.006.
3
Risk adapted chemoprevention for prostate cancer: an option?前列腺癌的风险适应性化学预防：一种选择？
Recent Results Cancer Res. 2014;202:79-91. doi: 10.1007/978-3-642-45195-9_10.
4
Chemoprevention of prostate cancer: an updated view.前列腺癌的化学预防：更新的观点。
World J Urol. 2012 Apr;30(2):189-94. doi: 10.1007/s00345-011-0822-9. Epub 2012 Jan 12.
5
[Role of 5 alpha-reductase inhibitors in the chemoprevention of prostate cancer].5α-还原酶抑制剂在前列腺癌化学预防中的作用
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2011 Oct;33(5):582-6.
6
Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults.5α-还原酶抑制剂治疗与老年男性前列腺癌死亡率的相关性。
JAMA Netw Open. 2019 Oct 2;2(10):e1913612. doi: 10.1001/jamanetworkopen.2019.13612.
7
Chemoprevention in prostate cancer: identifying patients at greatest risk may provide greatest value.前列腺癌的化学预防：识别风险最高的患者可能会带来最大价值。
Am J Manag Care. 2013 Mar-Apr;19 Spec No. 3:E8.
8
5α-Reductase inhibitors for prostate-cancer prevention.用于预防前列腺癌的5α-还原酶抑制剂。
N Engl J Med. 2011 Dec 15;365(24):2340. doi: 10.1056/NEJMc1112146.
9
Chemoprevention in Prostate Cancer: Current Perspective and Future Directions.前列腺癌的化学预防：当前视角与未来方向。
Cold Spring Harb Perspect Med. 2018 Oct 1;8(10):a030494. doi: 10.1101/cshperspect.a030494.
10
Role of 5α-reductase inhibitors in prostate cancer prevention and treatment.5α-还原酶抑制剂在前列腺癌防治中的作用。
Urology. 2012 Jun;79(6):1197-205. doi: 10.1016/j.urology.2012.01.024. Epub 2012 Mar 23.
引用本文的文献
1
Structures of Mammeasins P and Q, Coumarin-Related Polysubstituted Benzofurans, from the Thai Medicinal Plant (Miq.) T. Anders.: Anti-Proliferative Activity of Coumarin Constituents against Human Prostate Carcinoma Cell Line LNCaP.从泰国药用植物（Miq.）T. Anders.中提取的香豆素相关多取代苯并呋喃类化合物 Mammeasins P 和 Q 的结构：香豆素成分对人前列腺癌细胞系 LNCaP 的抗增殖活性
Pharmaceuticals (Basel). 2023 Feb 3;16(2):231. doi: 10.3390/ph16020231.
2
Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting.前列腺癌细胞存活的机制及其治疗靶点。
Int J Mol Sci. 2023 Feb 2;24(3):2939. doi: 10.3390/ijms24032939.
3
Is Early Surgical Treatment for Benign Prostatic Hyperplasia Preferable to Prolonged Medical Therapy: Pros and Cons.良性前列腺增生的早期手术治疗相较于长期药物治疗是否更可取：利弊分析
Medicina (Kaunas). 2021 Apr 9;57(4):368. doi: 10.3390/medicina57040368.
4
Hormonal Therapy for Prostate Cancer.前列腺癌的激素治疗。
Endocr Rev. 2021 May 25;42(3):354-373. doi: 10.1210/endrev/bnab002.
本文引用的文献
1
Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors-A Large Population-Based Prospective Study.接受 5α-还原酶抑制剂治疗的男性患前列腺癌的风险：一项大型基于人群的前瞻性研究。
J Natl Cancer Inst. 2018 Nov 1;110(11):1216-1221. doi: 10.1093/jnci/djy036.
2
Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.利用医疗保险索赔数据评估前列腺癌预防试验中非那雄胺的长期前列腺癌风险。
J Natl Cancer Inst. 2018 Nov 1;110(11):1208-1215. doi: 10.1093/jnci/djy035.
3
5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia.5-α还原酶抑制剂与接受良性前列腺增生治疗男性的前列腺癌死亡风险
Mayo Clin Proc. 2016 Dec;91(12):1717-1726. doi: 10.1016/j.mayocp.2016.07.023. Epub 2016 Oct 27.
4
5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.5α-还原酶抑制剂与前列腺癌男性癌症相关死亡率的关系。
JAMA Oncol. 2015 Jun;1(3):314-20. doi: 10.1001/jamaoncol.2015.0387.
5
Long-term survival of participants in the prostate cancer prevention trial.前列腺癌预防试验参与者的长期生存情况。
N Engl J Med. 2013 Aug 15;369(7):603-10. doi: 10.1056/NEJMoa1215932.
6
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.5α还原酶抑制剂用于前列腺癌预防的风险与益处。
N Engl J Med. 2011 Jul 14;365(2):97-9. doi: 10.1056/NEJMp1106783. Epub 2011 Jun 15.
7
Effect of dutasteride on the risk of prostate cancer.度他雄胺对前列腺癌风险的影响。
N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.
8
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.非那雄胺不会增加高级别前列腺癌的风险：一种偏差调整建模方法。
Cancer Prev Res (Phila). 2008 Aug;1(3):174-81. doi: 10.1158/1940-6207.CAPR-08-0092. Epub 2008 May 18.
9
The influence of finasteride on the development of prostate cancer.非那雄胺对前列腺癌发生发展的影响。
N Engl J Med. 2003 Jul 17;349(3):215-24. doi: 10.1056/NEJMoa030660. Epub 2003 Jun 24.
Zotero 插件